Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 22, 2017 09:59 ET | Source: Adaptimmune Therapeutics plc

James Noble, Adaptimmune CEO, to Participate in Upcoming Leerink Partners Roundtable Series: Rare Disease & Immuno-Oncology

PHILADELPHIA and OXFORD, U.K., Sept. 22, 2017 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that James Noble,...
September 07, 2017 07:30 ET | Source: Adaptimmune Therapeutics plc

GSK Exercises Option over SPEAR T-cell Therapy Program Targeting NY-ESO

PHILADELPHIA and OXFORD, United Kingdom, Sept. 07, 2017 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that...
August 30, 2017 08:00 ET | Source: Adaptimmune Therapeutics plc

Adaptimmune to Present at Upcoming CAR-TCR Summit; CEO James Noble to be a Keynote Speaker

PHILADELPHIA and OXFORD, U.K., Aug. 30, 2017 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in the use of TCR engineered T-cell therapy to treat cancer, today announced its...
August 03, 2017 07:30 ET | Source: Adaptimmune Therapeutics plc

Adaptimmune Reports Second Quarter 2017 Financial Results

– A registered direct offering in April combined with a public offering in March raised net proceeds of $103.2 million; operations funded through to late 2019 – – Enrolling 9 clinical studies...
July 31, 2017 16:00 ET | Source: Adaptimmune Therapeutics plc

Adaptimmune to Report Second Quarter 2017 Financial Results on August 3, 2017

PHILADELPHIA and OXFORD, United Kingdom, July 31, 2017 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer will announce financial results for...
June 05, 2017 09:50 ET | Source: Adaptimmune Therapeutics plc

Adaptimmune Announces an Oral Presentation on Data from NY-ESO Study in Synovial Sarcoma and Four Trials in Progress Posters at the American Society of Clinical Oncology (ASCO) Annual Meeting

PHILADELPHIA and OXFORD, United Kingdom, June 05, 2017 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced an oral...
May 26, 2017 08:00 ET | Source: Adaptimmune Therapeutics plc

Adaptimmune Announces an Oral Presentation and Four Trials in Progress Posters at the American Society of Clinical Oncology (ASCO) Annual Meeting

PHILADELPHIA and OXFORD, United Kingdom, May 26, 2017 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced an oral...
May 25, 2017 08:00 ET | Source: Adaptimmune Therapeutics plc

Adaptimmune Announces Initiation of Study to Evaluate SPEAR T-Cell Therapy Targeting NY-ESO in Combination with KEYTRUDA® (pembrolizumab) in Multiple Myeloma

PHILADELPHIA and OXFORD, United Kingdom, May 25, 2017 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that it has...
May 16, 2017 07:59 ET | Source: Adaptimmune Therapeutics plc

Adaptimmune Announces Initiation of Study to Evaluate SPEAR T-Cell Therapy Targeting MAGE-A4 in Multiple Solid Tumors

PHILADELPHIA and OXFORD, U.K., May 16, 2017 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that it has initiated the...
May 10, 2017 07:30 ET | Source: Adaptimmune Therapeutics plc

Adaptimmune Reports First Quarter 2017 Financial Results

– Offerings in March and April raised net proceeds of $103.2 million; operations funded through to late 2019 – – Initiated study with wholly-owned AFP SPEAR T-cells – – Initial data...